Citation: | SUN Zhuolin, LIU Jingwei, KUANG Changchun. Inhibitions and mechanisms of amygdalin in non-small cell lung cancer NCI-H1299 cell line invasion in vitro[J]. Journal of China Pharmaceutical University, 2016, 47(4): 479-482. DOI: 10.11665/j.issn.1000-5048.20160415 |
[1] |
Reck M,Popat S,Reinmuth N,et al.Metastatic non-small-cell lung cancer(NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2014,25(Suppl 3):iii27-39.
|
[2] |
Bolarinwa IF,Orfila C,Morgan MR.Amygdalin content of seeds,kernels and food products commercially-available in the UK[J].Food Chemistry,2014,152:133-139.
|
[3] |
Makarevi 'c J,Rutz J,Juengel E,et al.Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2[J].PLoS One,2014,9(8):e105590.
|
[4] |
Niu G,Ye T,Qin L,et al.Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin β4[J].FASEB J,2015,29(1):131-140.
|
[5] |
Matsubara D,Kishaba Y,Yoshimoto T,et al.Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer[J].Pathol Int,2014,64(11):560-568.
|
[6] |
Song JL,Nigam P,Tektas SS,et al.MicroRNA regulation of Wnt signaling pathways in development and disease[J].Cell Signal,2015,27(7):1380-1391.
|
[7] |
Sulzmaier FJ,Jean C,Schlaepfer DD.FAK in cancer:mechanistic findings and clinical applications[J].Nat Rev Cancer,2014,14(9):598-610.
|
[8] |
Fumarola C,Bonelli MA,Petronini PG,et al.Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer[J].Biochem Pharmacol,2014,90(3):197-207.
|
[9] |
Calderaro J,Rebouissou S,de Koning L,et al.PI3K/AKT pathway activation in bladder carcinogenesis[J].Int J Cancer,2014,134(8):1776-1784.
|
[10] |
Liu Y,Wang TT,Chen L.Synthesis and antitumor activity of isosteviol derivatives[J].J China Pharm Univ(中国药科大学学报),2016,47(1):48-53.
|